Cosmos Health’s C-Sept PRO Gains Strong Traction Across Leading Greek Public and Private Hospital Groups, With Annualized Sales Poised to Exceed $1.3 Million at Approximately 72% Gross Margin
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) reported accelerating traction for its proprietary antiseptic C-Sept PRO in leading Greek public and private hospital groups. Average sales exceeded $93,000 per month over six months, rising above $108,000 per month recently, putting annualized sales above $1.3 million at roughly 72% gross margin.
According to Cosmos Health, this creates a high-margin, recurring hospital revenue stream in Greece, with plans to expand the hospital-focused antiseptics business into additional European markets over time.
Positive
- C-Sept PRO annualized sales projected above $1.3 million
- Approximate annualized gross profit of $0.9 million at ~72% margin
- Recent monthly sales accelerated to over $108,000
- High-margin, recurring revenue from Greek hospital channel
- Adoption across leading public and private Greek hospital groups
- Planned expansion of hospital antiseptics business into more European markets
Negative
- None.
News Market Reaction – COSM
In the Jun 24 session, COSM declined 0.95%, reflecting a mild negative market reaction. Argus tracked a trough of -8.0% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Crypto Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 22 | Contract manufacturing update | Positive | -4.2% | Orderbook above 25M units and profit potential over $10M annually. |
| Jun 17 | New CM agreement | Positive | -3.2% | Five‑year, 2.86M‑unit dermatology contract manufacturing deal with Pharmex. |
| Jun 15 | US portfolio update | Positive | +14.2% | 18 Series nutraceutical launch with $22.7M+ revenue and $17.0M gross profit targets. |
| Jun 12 | New CM orders | Positive | +1.6% | 253,657 new contract manufacturing units from Nassington and Verisfield. |
| Jun 12 | Antiseptic sales update | Positive | +1.6% | C‑Scrub and C‑Sept annualized sales above $1.5M with 70%+ margins. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive expansion updates under the same tag often see mixed reactions, with slightly more aligned than divergent moves.
Key Terms
chlorhexidine gluconate medical
w/v technical
venipunctures medical
vascular catheterization medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, June 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided an update on the growing momentum of C-Sept™ PRO, a proprietary antiseptic solution from its high-margin infection-control portfolio, across leading public and private hospital groups in Greece.
C-Sept PRO has generated average monthly sales exceeding
C-Sept PRO is a professional-grade antiseptic alcohol solution combining
In a hospital environment, where infection control is essential to patient safety, antiseptic products such as C-Sept PRO are used routinely and repeatedly across departments, supporting durable, recurring demand.
The Company believes its hospital business represents a new, high-margin revenue generator for Cosmos Health. With gross margins of approximately
Over time, the Company intends to extend its hospital-focused antiseptics business into additional European markets, leveraging Cana Laboratories' European GMP-certified manufacturing platform and Cosmos Health's established distribution footprint.
Greg Siokas, CEO of Cosmos Health, stated: "C-Sept PRO's accelerating momentum across leading Greek hospital groups demonstrates the strength of our proprietary antiseptics franchise and the significant opportunity within the hospital channel. With annualized sales set to exceed
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c83131c3-9ee4-4030-9c10-2650d75d13ce
